GO
Loading...

One Word for This Stock - Poop!

As this year's JP Morgan Healthcare Conference, sometimes called the Super Bowl of Biotech, gets underway, Cramer said he was very excited to hear from a relatively small, speculative diagnostics company called Exact Sciences, (TICKER: EXAS)

"It has a potentially game-changing product, one that could help save tens of thousands of lives," he said.

How are they going to do this? With poop - really.


Every year, fifty thousand people die from colon cancer here in the United States—it's among the most lethal forms of cancer and the most treatable, if detected early enough.

Therefore, after age 50, doctors urge patients to to get a colonoscopy every decade to screen for the disease.

Unfortunately, about half of all Americans that age don't do it.


High Tech Bathroom
Miguel S. Salmeron | Photodisc | Getty Images
High Tech Bathroom

The reason - getting a colonoscopy is an unappealing procedure: it's invasive, it's uncomfortable, and you have to fast while drinking gallons of colon cleanse beforehand.

"This is where Exact Sciences comes in," explained Cramer.

"They've developed a totally non-invasive stool test—just collect a sample at home at your leisure and send it into the lab—that can detect colon cancer with over 90% sensitivity, and it can catch pre-cancerous cells, too."

Cramer added the test is not intended to replace getting a colonoscopy, but it can tell you whether you really need one, and – perhaps more important - it could ultimately help catch colon cancer much earlier.

"Now, so far the data has been pretty darned positive, and the FDA is expected to render its decision on whether to approve the test next year. Almost as important, the government agency that oversees Medicare reimbursement is reviewing the test parallel with the FDA, which means they could decide whether or not to pay for it right after it potentially gets approved," Cramer added.

Of course that's not to say there aren't concerns about the stock. There are. There's a potentially high price for the test and there are rivals in the field.

Despite those concerns Cramer said the stock looks like an intriguing opportunity.

"I initially got behind Exact Sciences in October of 2010 and the stock is up 34.4% since then. If all goes well, and this is speculative so that's a genuine if, then this stock could have a lot more room to run," he said.

Learn more about this company. Hear from Kevin Conroy, the President and CEO of Exact Sciences in the video above.


Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Contact Mad Money

  • Showtimes

    U.S.
    Monday - Friday 6p ET
    Australia
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.

Mad Money Moments

Cramer's New Book